# OnCo record paper-papmet-pal-lancet-2021 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-papmet-pal-lancet-2021/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-papmet-pal-lancet-2021" ;
  schema:name "PAPMET (SWOG 1500): cabozantinib versus sunitinib for metastatic papillary renal cell carcinoma"@en ;
  schema:description "In the first randomised trial to show a benefit in papillary kidney cancer, the MET-targeting kinase inhibitor cabozantinib delayed progression and tripled the response rate compared with sunitinib, while two other MET inhibitors did not."@en ;
  schema:url <https://onco.cc/key-papers/paper-papmet-pal-lancet-2021/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S0140-6736(21)00152-5>, <https://pubmed.ncbi.nlm.nih.gov/33592176/> ;
  schema:sameAs <https://doi.org/10.1016/S0140-6736(21)00152-5> ;
  schema:datePublished "2021"^^xsd:gYear ;
  schema:author "Pal SK, Tangen C, Thompson IM, et al." ;
  onco:cancers <https://onco.cc/cancers/papillary-rcc/> ;
  onco:drugs <https://onco.cc/drugs/cabozantinib/>, <https://onco.cc/drugs/crizotinib/>, <https://onco.cc/drugs/savolitinib/>, <https://onco.cc/drugs/sunitinib/> ;
  onco:trials <https://onco.cc/trials/papmet/> ;
  onco:journals <https://onco.cc/journals/lancet/> .